SINGAPORE — (BUSINESS WIRE) — Prestige BioPharma Limited (950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced positive efficacy and safety r…
The Result of the Phase 3 Study for Prestige BioPharma』s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology
SINGAPORE — (BUSINESS WIRE) — Prestige BioPharma Limited (950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, announced positive efficacy and safety r…